Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/21/2025

Reversal of Tenecteplase (TNK)

Key Pharmacologic Characteristics

  • The American Heart Association notes that tenecteplase is a genetically engineered tissue plasminogen activator with a terminal half-life of 65-132 minutes and initial disposition half-life of 17-24 minutes, meaning the drug's fibrinolytic effects dissipate relatively quickly after administration 1

Management of Major Bleeding Complications

  • The American College of Cardiology recommends that for life-threatening bleeding complications, management relies on supportive care, discontinuation of the drug, and administration of antifibrinolytic agents (cryoprecipitate, fresh frozen plasma, or tranexamic acid) 2
  • The European Society of Cardiology suggests assessing the bleeding source and severity, with intracranial hemorrhage occurring in approximately 1-2% of patients, while major non-cerebral bleeding occurs in 4-6% 2, 3
  • The American Heart Association advises obtaining emergency imaging for suspected intracranial hemorrhage 2
  • The American College of Cardiology recommends administering cryoprecipitate (10 units) or fresh frozen plasma (2-4 units) to replace fibrinogen and clotting factors depleted by fibrinolysis 2
  • The European Society of Cardiology suggests considering tranexamic acid (1 gram IV over 10 minutes) as an antifibrinolytic agent to inhibit plasminogen activation and stabilize clot formation 2
  • The American College of Cardiology notes that platelet transfusion may be necessary if thrombocytopenia is present or if the patient was on antiplatelet therapy 2

Special Considerations for Anticoagulated Patients

  • The American Heart Association recommends that for patients on direct factor Xa inhibitors (rivaroxaban, apixaban) or warfarin who develop bleeding after TNK, standard reversal protocols apply: prothrombin complex concentrate (PCC) for warfarin or factor Xa inhibitors, with dosing based on the specific agent and INR if applicable 4

Critical Pitfalls to Avoid

  • The European Society of Cardiology warns not to confuse TNK with streptokinase, as streptokinase causes antibodies and hypotension requiring specific management, while TNK does not 1
  • The American College of Cardiology advises not to delay supportive care waiting for a "reversal agent", as none exists, and time is critical in managing bleeding complications 2
  • The American Heart Association recommends monitoring high-risk patients closely, including elderly patients, those with low body weight, females, and patients with uncontrolled hypertension, as they have a higher bleeding risk 2, 1

Management of Bleeding Complications After Tenecteplase Administration

Patient Risk Factors and Bleeding Complications

  • Intracranial hemorrhage occurs in approximately 0.9-1.0% of patients, with risk factors including advanced age, lower weight, female gender, prior cerebrovascular disease, and hypertension on admission, according to the European Heart Journal 5